Daridorexant

FDA APPROVAL DATE: 01/07/2022

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A4 inducers, CYP3A4 inhibitors, Diltiazem, Efavirenz, Itraconazole, Ranitidine, Ranitidine, Rifampin


No available data on daridorexant use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. Risk increases when used with other central nervous system depressants. Avoid alcohol consumption with daridorexant.

Our database has 5 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
RESPIRATORY.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top